D. E. Shaw & Co., Inc. Astria Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 10,168 shares of ATXS stock, worth $93,037. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,168Holding current value
$93,037% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding ATXS
# of Institutions
107Shares Held
48.6MCall Options Held
48KPut Options Held
9.3K-
Perceptive Advisors LLC New York, NY6.49MShares$59.3 Million1.87% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$46.7 Million0.78% of portfolio
-
Vestal Point Capital, LP New York, NY4MShares$36.6 Million3.34% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$32.5 Million6.36% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$32.2 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $139M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...